Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.51 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.51 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.51 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29765773 | 1.00 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647146 | 1.00 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765708 | 0.94 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18133905 | 0.94 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646908 | 0.94 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17026468 | 0.94 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17621834 | 0.93 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17026315 | 0.92 | KRAS (0.57) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646878 | 0.92 | KRAS (0.57) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765896 | 0.92 | KRAS (0.57) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | claimed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 380/4885HMOX2 2619/4885 |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 380/4885HMOX2 2619/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 247/4885HMOX2 3757/4885 |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | KRAS 1369/4885EGFR 4238/4885HMOX2 4345/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | KRAS 1/4885EGFR 16/4885HMOX2 2281/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885EGFR 16/4885HMOX2 2281/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885EGFR 16/4885HMOX2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.